Stock data
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA) reported revenue of US$67.67M and net income of -US$412.69M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$67.67M | — | -US$440.99M | -US$412.69M | — |
| 2024 | US$57.88M | — | -US$534.26M | -US$519.02M | — |
| 2023 | US$36.27M | — | -US$515.29M | -US$481.19M | — |
| 2022 | US$52.12M | — | -US$458.16M | -US$474.19M | — |
| 2021 | US$33.05M | — | -US$267.85M | -US$267.89M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$7.66M | -US$106.63M | — |
| 2026-03-31 | US$15.05M | -US$96.23M | — |
| 2025-12-31 | US$23.02M | -US$95.79M | — |
| 2025-09-30 | US$13.78M | -US$101.32M | — |
| 2025-06-30 | US$14.24M | -US$101.25M | — |
| 2025-03-31 | US$16.63M | -US$114.33M | — |
| 2024-12-31 | US$12.87M | -US$128.90M | — |
| 2024-09-30 | US$9.11M | -US$135.71M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.